Abstract:Abstract Immune checkpoint inhibitors targeting the PD1/PD-L1 and CTLA4 signaling axes have made a significant impact in the treatment of some solid tumors, particularly melanoma and non-small-cell lung carcinoma. While triple-negative breast cancers (TNBC) typically have poorer clinical outcomes due in part to a lack of targeted therapies, they are often more immunogenic than other types of breast cancer.1 Some forms of chemotherapy, including microtubule-targeting agents, have been proposed to enhance the efficacy of immunotherapy,2 which has resulted in the evaluations of combinations of these drugs in preclinical and clinical studies. Most notably, the combination of the PD-L1 inhibitor atezolizumab with the taxane nab-paclitaxel was shown to prolong progression-free survival in patients with metastatic TNBC.3 Although it is known that paclitaxel can function as a TLR4 agonist leading to activation of the innate immune system, there has been little comparison of the immunogenic effects elicited by different clinically used MTAs for the treatment of TNBC. We evaluated the effects of 5 distinct MTAs used for the treatment of TNBC, paclitaxel, docetaxel, ixabepilone, vinorelbine, and eribulin, on the expression of antitumor cytokines and other immunomodulatory genes in myeloid and in TNBC cells. Our results show that the expression signature generated by the microtubule stabilizers, paclitaxel, docetaxel, and ixabepilone, was markedly different from the signature elicited by the microtubule destabilizers eribulin and vinorelbine. The microtubule destabilizers caused upregulation of type 1 interferons and interferon-stimulated-genes (ISGs), effects not seen with the microtubule stabilizers. A time course analysis revealed that the transcriptional upregulation of the ISG CXCL10 by eribulin occurred before the expression of interferons. Mechanistically, microtubule destabilizer-induced expression of c-Jun which could upregulate the early expression of CXCL10 through activation of the AP-1 complex. The eribulin-mediated induction of type 1 interferons is similar to the expression signature promoted by the cGAS-STING pathway that has been shown to enhance the efficacy of checkpoint inhibitors,4 suggesting that microtubule destabilizers, but not stabilizers, can promote signaling through this pathway. Together, these results provide evidence that distinct MTAs have different immune modulatory properties and suggest that the specific immune signatures initiated by the different MTAs need to be considered for their optimal use with checkpoint inhibitors. These studies were funded by Eisai. 1. Liu, Z., Li, M., Jiang, Z. & Wang, X. A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer. Transl Oncol 11, 311-329, (2018). 2. Emens, L. A. & Middleton, G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res 3, 436-443, (2015). 3. Schmid, P. et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 379, 2108-2121, (2018). 4. Cheng, N. et al. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer. JCI Insight 3, (2018). Citation Format: Charles S Fermaintt, Shayne Hastings, Susan L Mooberry, April L Risinger. Eribulin treatment activates type 1 IFNs to promote a gene expression signature associated with antitumor immunity [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P5-05-03.

hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC

Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer

JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer.

Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

RAS/MAPK Activation is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.

Cancer-specific type-I interferon receptor signaling promotes cancer stemness and effector CD8+ T-cell exhaustion

Regulatory interacting network between the immunomodulatory non-coding RNAs: miR-17-5p, MALAT1 and H19 lncRNAs in modulating the tumour microenvironment in TNBC

Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade

High-throughput transcriptome profiling indicates ribosomal RNAs to be associated with resistance to immunotherapy in non-small cell lung cancer (NSCLC)

Interplay between miR-17-5p and MALAT-1 shapes the cytokine storm in triple negative breast cancer (TNBC) tumor microenvironment

Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas

HRS mediates tumor immune evasion by regulating proteostasis-associated interferon pathway activation

Essential role of MED1 in the transcriptional regulation of ER-dependent oncogenic miRNAs in breast cancer

Human NLRC4 expression promotes cancer survival and associates with type I interferon signaling and immune infiltration

Ribosomal Biogenesis Hyperactivation and ErbB signalling Mediated Network Rewiring Causes Adaptive Resistance to FGFR2 Inhibition

Tumor-intrinsic RGS1 Potentiates Checkpoint Blockade Response Via ATF3-IFNGR1 Axis

Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses

RGMb impacts partial epithelial‐mesenchymal transition and BMP2‐Induced ID mRNA expression independent of PD‐L2 in nonsmall cell lung cancer cells

Abstract P5-05-03: Eribulin treatment activates type 1 IFNs to promote a gene expression signature associated with antitumor immunity

The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1

700 Increasing MHC-I expression to potentiate immune checkpoint blockade therapy